Amendments for: 172-2022-2023-Q2-995430

Agreement Value: $5,426,172.00
Agreement: COVID-19 Rapid Response: Assessment of the Effect of lung-directed Site-Specific Immunomodulator (SSI) in clinical trial QBKPN-CV-01: Assessment of the Effect of QBKPN Site-Specific Immunomodulator (SSI) on Innate Immunity and COVID-19 Vaccine Immune Response and Maintenance in Adults 65 Years of Age or Older (995430). Sep 1, 2022 - Mar 31, 2024
Description:

This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Organization: National Research Council Canada
Recipient: Qu Biologics Inc. (For-profit organization)
Location: Burnaby, British Columbia, CA V5G 4X4
Type: Contribution
Additional Information:

This agreement has been amended 1 time(s). The total amended value is 500,000 dollars.

Federal Riding Name: Burnaby South (59003)
Program Name: Industrial Research Assistance Program – Contributions to Firms

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code: 541710

Agreement Value: $5,426,172.00
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The total amended value is 500,000 dollars.

Agreement Value: $4,926,172.00
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The total amended value is -1,732,878 dollars.

Agreement Value: $6,659,050.00
Agreement: COVID-19 Rapid Response: Assessment of the Effect of lung-directed Site-Specific Immunomodulator (SSI) in clinical trial QBKPN-CV-01: Assessment of the Effect of QBKPN Site-Specific Immunomodulator (SSI) on Innate Immunity and COVID-19 Vaccine Immune Response and Maintenance in Adults 65 Years of Age or Older (995430). Sep 1, 2022 - Mar 31, 2024
Description:

This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Organization: National Research Council Canada
Recipient: Qu Biologics Inc. (For-profit organization)
Location: Burnaby, British Columbia, CA V5G 4X4
Type: Contribution
Federal Riding Name: Burnaby South (59003)
Program Name: Industrial Research Assistance Program – Contributions to Firms

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code: 541710